THERACRYF PLC
The results will be available via the
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the
Contact:
Dr
Tel: +44 (0)1625 315 090
Email: enquiries@theracryf.com
Tel: +44 20 7220 0500
Tel: +44 207 457 2020
Email: theracryf@Instinctif.com
About
TheraCryf is the clinical stage drug development company focussing on oncology and neuropsychiatry. The Company has a broad clinical and preclinical pipeline in indications such as neurodevelopmental disorders, glioblastoma, addiction, anxiety and narcolepsy [orphan indications]. Its strategy is to generate compelling data sets to proof of concept and/or later phase II to partner its clinical programmes with mid-size to large pharma. As well as a number of industry partnerships with companies, including Stalicla, in neurodevelopment disorders and has sourced programmes from companies such as Takeda and Shire, the Company has worked with and has ongoing collaborations with major universities, hospitals and government organisations such as the
(C) 2024 Electronic News Publishing, source
